Heidelberg Pharma is a drug development company that provides pre-clinical drug discovery and development services for the development of anti-cancer and anti-inflammatory drugs to pharmaceutical and biotechnology industries. It offers services, such as explorative pharmacology, drug metabolism and pharmacokinetics analysis, and molecular biology in the fields of oncology or inflammatory/autoimmune diseases. The company is focused on oncology and is the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate technology platform and to advance the biological mode of action of the toxin as a novel therapeutic principle.